Carbohydrate malabsorption as a potentiator of infectious antibiotic-associated diarrhea
Active Project Grant Awarded Last action
- Award ID
- F30AI188645
- Recipient
-
Case Western Reserve University UEI HJMKEF7EJW69
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $110,228
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 4% complete
- Originally
- Place of performance
- Cleveland, OH 44106, USA
Award details come from USAspending.gov.
About this award
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health under the Department of Health and Human Services, awarded Case Western Reserve University $110,228 on October 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855).
The award funds research investigating the mechanisms linking carbohydrate malabsorption and antibiotic-associated diarrhea through immunoglobulin A deficiency. The research proposes that antibiotic-induced disruption of microbial carbohydrate catabolism leads to water accumulation and dilution of intestinal immunoglobulin A, rendering the host susceptible to toxin-mediated bacterial damage. The first project aim establishes dietary carbohydrate catabolism as necessary to maintain proper water balance and normal immunoglobulin A concentrations in the lower intestine; the second aim examines how immunoglobulin A dilution increases susceptibility to toxin-mediated damage in the colon. The research will be conducted in the Stappenbeck Lab at Case Western Reserve University.
Performance extends from October 5, 2026, through April 30, 2028. Work is performed in Cleveland, Ohio. Case Western Reserve University's Office of Research Administration, operating in affiliation with University Hospitals of Cleveland, received the award as the prime recipient.
Description
- Abstract
- Antibiotic-associated diarrhea is a common and potentially life-threatening adverse event that affects the tolerability and therefore efficacy of these drugs. Most cases have been postulated to be due to malabsorption of nutrients secondary to the disruption of microbial communities capable of catabolizing them, while a minority but clinically serious number of cases are due to infection with toxin-producing pathogens. This study proposes a previously unappreciated link between malabsorptive and infectious antibiotic-associated diarrhea through the compromising effect of antibiotics on immunoglobulin a (IGA) levels in the intestine. IGA is an important immune mediator capable of neutralizing bacterial toxins, and selective IGA deficiency following antibiotic treatment is a common clinical occurrence. The stappenbeck lab, i.e., the research environment this fellowship will be completed in, has an extensive and recent publication history regarding the function of IGA in the context of infection and how these functions are compromised by actions of the microbiota. Preliminary data generated in this lab suggests that water accumulation in the lower intestine underlies reduced fecal IGA concentrations following vancomycin treatment, and that the degree of this water accumulation positively correlates with dietary carbohydrate intake. The overarching hypothesis of this proposal is that vancomycin-induced disruption of microbial carbohydrate catabolism underlies water accumulation and dilution of luminal IGA in the lower intestine (aim 1), and that this dilution of luminal IGA renders the host susceptible to toxin-mediated damage in the colon (aim 2). Aim 1 focuses on establishing dietary carbohydrate catabolism as a necessary function of the microbiota in maintaining proper water balance and thereby normal IGA concentrations in the lower intestine. This will be experimentally tested by investigating the relative contribution of vancomycin-sensitive microbes to carbohydrate catabolism in vivo, and the functional relevance of this contribution through rescue experiments involving microbes capable or incapable of catabolizing dietary carbohydrates. Aim 2 focuses on the clinical implications of reduced colonic IGA concentrations following vancomycin treatment through in vitro and in vivo neutralization and challenge assays using bacterial toxins relevant to infectious antibiotic-associated diarrhea. The aims in this proposal have been made with close consideration of the goals detailed in the training plan, those being i) furthering technical abilities in the study of microbes and their effects on immunity, II) providing the basis for improvement of written and verbal scientific communication, and III) serving as a foundation in addressing clinical problems through experimental investigation. Successful completion of these aims will both prepare the applicant for a future career as a physician-scientist in the long-term, while also clarifying mechanisms underlying antibiotic-associated diarrhea and immunodeficiency to benefit human health in the short-term.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $55,114 | |
| Amendment | $55,114 | |
| Original award | $0 |
Quick answers
Who received award F30AI188645?
F30AI188645 was awarded to Case Western Reserve University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on October 5, 2026.
How much is award F30AI188645 worth?
$110,228 has been obligated on F30AI188645.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award